The Lexington, MA-based company said it will use the proceeds to support the Revita T2Di pivotal clinical trial of the Revita DMR technology.

Lund University researchers found the test demonstrated promise in discriminating between persons with and without Alzheimer's disease.

Dexcom CEO says the company has made progress on "several fronts" regarding the G7 pivotal trials, however the company is no longer disclosing timeline specifics.

Researchers from Brigham and Women's Hospital conducted a systematic review and meta-analysis, analyzing data from more than 3,000 specimens to compare COVID-19 detection approaches.

The Santa Clara, CA-based company said the AMBULATE Same-Day Discharge will enroll 150 patients in up to 10 centers to evaluate the VASCADE MVP Venous Vascular Closure System.

The CorNeat KPro implant is designed to replace deformed, scarred or opacified corneas and is expected to fully rehabilitate the vision of corneally blind patients immediately following implantation.

CVRx's BeAT-HF study represents a major turning point in heart failure therapy and ushers in a new era for breakthrough medical devices.

The Wayne, PA-based company announced the results of the Tack Optimized Balloon Angioplasty (TOBA) II BTK clinical trial during the 2020 Vascular Interventional Advances (VIVA) Late-Breaking Clinical Trial livestream.

It’s exciting to start a company with a new medical device. Don’t let that excitement get in the way of planning.

Boston, MA-based Empatica will work with BARDA to validate, Aura, a system with the potential to alert individuals when it detects a likely COVID-19 infection, enabling them to self-isolate and seek early treatment.